We have a vision

By 2050, the number of people suffering from Alzheimer’s disease will have tripled, affecting a projected 13.8 million people in the US alone. Early detection of this dramatic medical condition is crucial. We’re focused on a solution.

About Us

Optina Diagnostics specializes in the development of technology for early, non-invasive detection of disease via Retinal Deep PhenotypingTM. With a primary focus on the diagnosis of Alzheimer’s disease, Optina addresses the pressing need of millions of patients worldwide suffering from memory loss.

In Feb 2020, Optina received the 510(k) clearance for its ophthalmic camera by the U.S. Food and Drug Administration (FDA). Optina also obtained Breakthrough Device Designation from the FDA for its first diagnostic test for the detection of the likely cerebral amyloid status.

Currently, there’s no single diagnostic test for patients who are experiencing symptoms of cognitive decline. Instead, physicians use a process of elimination, ruling out other health concerns via cognitive assessments, medical and family history. This process may take years, and eventually requires invasive and costly tests.

Optina aims to establish a New Paradigm and transform detection and understanding of memory loss by bringing cutting-edge eye imagery and artificial intelligence to your local eye clinic.

Worldwide, nearly 44 million people have Alzheimer’s or a related dementia.

Our experts

Optina Diagnostics is made up of a driven and dynamic team of experts in the areas of business development, research, and finance.

David Lapointe, M. Sc.

President and CEO

Chantal Miklosi


Jean-Philippe Sylvestre, ing., M.Sc., Ph.D.


Claudia Chevrefils, ing., Ph.D.


Marie-Claude Marchand Bsc. MBA

Vice-President Business Development

Marie-Andrée Tremblay, ing.

Scientific Team

George Mallin, MSME, MBA

Product Manager

Gabriel Dignard

Scientist in image analysis

Sébastien Blais Ouellette, Ph.D.

Board of Directors

Jean Daniel Arbour

Board of Directors